Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones

被引:29
作者
Aboraia, Ahmed S. [1 ]
Makowski, Bart [2 ]
Bahja, Alba [1 ]
Prosser, David [2 ]
Brancale, Andrea [1 ]
Jones, Glenville [2 ]
Simons, Claire [1 ]
机构
[1] Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada
[2] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3NB, S Glam, Wales
关键词
Benzylidene tetralones; Benzyl tetralones; CYP24A1; CYP27A1; Enzyme inhibition; Molecular modelling; PROSTATE-CANCER CELLS; VITAMIN-D ANALOGS; 1-ALPHA; 25-DIHYDROXYVITAMIN D-3; ENZYMES; INACTIVATION; HYDROXYLASE; ACTIVATION; POTENT;
D O I
10.1016/j.ejmech.2010.07.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones were prepared, using an efficient synthetic scheme, and evaluated for their inhibitory activity against cytochrome P450C24A1 (CYP24A1) hydroxylase. In general the reduced benzyl tetralones were more active than the parent benzylidene tetralones. The 2-ethyl and 2-trifluoromethyl benzyl tetralone derivatives (4c and 4b) showed optimal activity in this series with IC(50) values of 1 92 mu M and 2.08 mu M, respectively compared with the standard ketoconazole IC(50) 0.52 mu M. The 2-bromobenzyl tetralone (4d) showed a preference for CYP27A1 (IC(50) 59 nM) over CYP24A1 (IC(50) 163 mu M) and may be a useful lead in CYP27A1 inhibition studies The 2-ethylphenyl benzyl derivative (9c), which showed weak activity against the wild type CYP24A1 (IC(50) 25.57 mu M), exhibited enhanced inhibitory activity towards L148F and M416T mutants, this difference in activity for the L148F mutant has been explained using molecular modelling (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:4427 / 4434
页数:8
相关论文
共 20 条
[1]  
[Anonymous], MOL OPERATING ENV 20
[2]  
Cho BT, 2002, TETRAHEDRON-ASYMMETR, V13, P1209
[3]   Homology model of 1α,25-dihydroxyvitamin D3 24-hydroxylase cytochrome P450 24A1 (CYP24A1):: Active site architecture and ligand binding [J].
Gomaa, Mohamed Sayed ;
Simons, Claire ;
Brancale, Andrea .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2007, 104 (1-2) :53-60
[4]   Current understanding of the molecular actions of vitamin D [J].
Jones, G ;
Strugnell, SA ;
DeLuca, HF .
PHYSIOLOGICAL REVIEWS, 1998, 78 (04) :1193-1231
[5]  
Jones G, 2006, ANTICANCER RES, V26, P2589
[6]   Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase:: 24-sulfoximine analogues of the hormone 1α,25-dihydroxyvitamin D3 [J].
Kahraman, M ;
Sinishtaj, S ;
Dolan, PM ;
Kensler, TW ;
Peleg, S ;
Saha, U ;
Chuang, SS ;
Bernstein, G ;
Korczak, B ;
Posner, GH .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (27) :6854-6863
[7]   Inhibition of retinoic acid metabolising enzymes by 2-(4-aminophenylmethyl)-6-hydroxy-3,4-dihydronaphthalen-1(2H)-one and related compounds [J].
Kirby, AJ ;
Le Lain, R ;
Maharlouie, F ;
Mason, P ;
Nicholls, PJ ;
Smith, HJ ;
Simons, C .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2003, 18 (01) :27-33
[8]   Promise of vitamin D analogues in the treatment of hyperproliferative conditions [J].
Masuda, S ;
Jones, G .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :797-808
[9]  
Perrin D.D., 1980, PURIFICATION LAB CHE, VSecond
[10]   Potent, low-calcemic, selective inhibitors of CYP24 hydroxylase:: 24-sulfone analogs of the hormone 1α,25-dihydroxyvitamin D3 [J].
Posner, GH ;
Crawford, KR ;
Yang, HW ;
Kahraman, M ;
Jeon, HB ;
Li, HB ;
Lee, JK ;
Suh, BC ;
Hatcher, MA ;
Labonte, T ;
Usera, A ;
Dolan, PM ;
Kensler, TW ;
Peleg, S ;
Jones, G ;
Zhang, AQ ;
Korczak, L ;
Saha, U ;
Chuang, SS .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5) :5-12